Nag Rayapureddi

Bayer Corp. manufactures and markets pharmaceutical, healthcare, nutrition and materials products. The firm offers consumer care, diagnostics, diabetes and animal health products. It also provides material science products, which include coating, adhesive and sealant raw materials polycarbonates polyurethanes and thermoplastic polyurethane elastomers. The company was founded in 1973 and is based in Whippany, NJ.

Serenex, Inc. operates as a biotechnology company that develops drugs for tumors and cancers of the blood and bone marrow. Its products include drugs for chemotherapy treatments as well as inhibitor compounds. Serenex was founded by George Young and Timothy Haystead in 2000 and is headquartered in Durham, NC.

Cylene Pharmaceuticals, Inc. discovers, develops and commercializes small molecule drugs. It develops molecule drugs to treat life-threatening diseases, with a particular emphasis in oncology. The firm drug discovery platform, STAND has delivered a diverse portfolio of drug candidates that target the multiple pathways critical for the support, maintenance of cancer cells and that address unmet medical needs with substantial markets. The company was founded in 1997 by Thomas James Farrell and Daniel Douglas Von Hoff and is headquartered in San Diego, CA.

Conforma Therapeutics Corp. designs and develops drugs for treatment of cancer. It also develops applications in the areas of medicine, including inflammation, virology and central nervous system disorders. The company was founded in 1999 and is headquartered in Cambridge, MA.

Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC.

Cavion, Inc. engages in development of pharmaceuticals products. It produces oncology drugs to treat solid tumors that selectively inhibits the t-type calcium channel. The company was founded by Andrew J. Krouse, Lloyd S. Gray, and Timothy L. Macdonald in 2005 and is headquartered in Charlottesville, VA.

Cabrellis Pharmaceuticals Corp. manufactures medical products. The firm develops therapies for treatment of cancer. The company was founded by Thomas M. Estok, Lawrence C. Fritz and Christopher C. LeMasters in 2006 and is headquartered in Summit, NJ.

Protagonist Pty Ltd. operates as a clinical-stage biopharmaceutical company. Its proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded on September 19, 2001 and is headquartered in Brisbane, Australia.

FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA.

Nimbus Therapeutics LLC provides drug discovery research services. It is a computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. The company was founded by Bruce Lee Booth in 2009 and is headquartered in Cambridge, MA.

Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC.

Esanex, Inc. manufactures and develops drugs for cancer treatment. Its products include orally active Hsp90 inhibitors. The company was founded in 2011 and is headquartered in Indianapolis, IN.

Symic Bio, Inc. develops new category of therapeutics. The company studies treatments for osteoarthritis and cardiovascular ailments. The firm developed a new therapeutic category of bioconjugates that directly target the extracellular matrix, the biologically active environment which plays critical roles for cell proliferation, migration, differentiation and survival. The company was founded by Kate Stuart and John Paderi in 2012 and is headquartered in San Francisco, CA.

Innocrin Pharmaceuticals Holdings LLC discovers and develops oral inhibitors for the treatment of Castration-Resistant Prostate Cancer (CRPC). The company is headquartered in Durham, NC.

Symic Holdings LLC develops new category of therapeutics. The company was founded by John Paderi, Kate Stuart and Alyssa Panitch and is headquartered in Emeryville, CA.

Roche Diagnostics Corp. develops and manufactures diagnostic products. It offers anticoagulation management, blood gas and electrolytes, cholesterol and urinalysis products. The firm provides a broad portfolio of tools that help healthcare providers in the prevention, diagnosis and management of diseases like HPV, HIV, heart failure and diabetes, as well as other medical conditions, such as fertility and blood coagulation. Its products and services uses by researchers, physicians, patients, hospitals and laboratories worldwide. The company was founded in 1964 by Willard Eason and is headquartered in Indianapolis, IN.

Hydra Biosciences, Inc. develops pharmaceutical products. It is focused in major therapeutic areas, which include pain, inflammation, renal, anxiety, and pulmonary diseases. The company was founded by Laurie Bartlett Keating, Dean Y. Li, David E. Clapham, and Mark T. Keating in 2001 and is headquartered in Belmont, MA.

Trinity Biosystems, Inc. develops and formulates orally delivered bio-therapeutic macromolecules. It offers TriPex system, an approach to macromolecule delivery that works cooperatively with the natural physiology of the body. The system utilizes a specific and natural biological transport mechanism: a receptor-mediated transcellular transport pathway that allows passage through the mucosal epithelium and delivery of the therapeutic payload into the blood. The company was founded by Randall J. Mrsny on July 19, 2002 and is headquartered in Menlo Park, CA.

Part of Eli Lilly & Co., Lilly Research Laboratories is a company that engages in research and develops medicines. The company is based in Indianapolis, IN.

Numerate, Inc. operates as a technology platform company that leverages proprietary algorithms and cloud computing to transform the drug design process. The company was founded by Guido Lanza, Nigel P. Duffy, John Hampton Griffin and Brandon Allgood in 2007 and is headquartered in San Francisco, CA.

Lilly Ventures Fund I LLC seeks investment opportunities located in the North American and European regions. The fund targets companies operating in the fields of biotechnology, medical technology and healthcare IT. It provides financing for early stage capital requirements.

Nimbus Apollo, Inc. provides drug discovery research services. The company is headquartered in Cambridge, MA.

TEN63 Therapeutics provides drug development services. The American company was founded by Nancy Miller-Rich, Marcel Frenkel, Mark Hallen, Bruce Donald. Marcel Frenkel has been the CEO since incorporation.

Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning.

Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC.